Actively Recruiting
Phase 1 Study of NK Cell and CAR-T Cell Therapy for Children and Young Adults With Relapsed or Refractory Neuroblastoma or Osteosarcoma
Led by Baylor College of Medicine · Updated on 2026-07-21
27
Participants Needed
1
Research Sites
782 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety and effects of combining two types of specially modified immune cells, called i15.NKG2D.zeta-NK cells and C7R.GD2.CAR-T cells, in patients with neuroblastoma or osteosarcoma that have returned or not responded to previous treatments. These cancers express a substance called GD2 on their cells. This gene transfer study aims to find the highest safe dose of the NK cells combined with the T cells and to understand how long these cells remain in the blood and their impact on the cancer. The cells are genetically engineered to improve their ability to survive and fight the tumor environment. Patients own T cells are collected and modified to target GD2, while NK cells from healthy donors are modified to target the tumor environment. The modified cells are frozen and later infused into patients. Patients receive an infusion of NK cells first, followed five days later by an infusion of T cells. The NK cell infusion may be preceded by medication like Benadryl or Tylenol to reduce reactions and takes 1 to 10 minutes, followed by monitoring. Some patients may also receive chemotherapy before the NK cell infusion. After the T cell infusion, patients may stay in the hospital for up to four weeks for monitoring. The study tests three escalating dose levels of NK cells combined with a fixed dose of T cells. Participants undergo medical tests before treatment including physical exams, blood tests, imaging scans, and lung function tests. During and after treatment, they have regular follow-up visits for up to 15 years to monitor side effects, check tumor status, and measure how long the modified cells last in the body through blood samples. Additional tumor samples may be collected if procedures are done. Supportive care is provided as needed for any side effects. The main outcomes measured are dose-related toxicities and the maximum safe dose of NK cells with T cells, as well as tumor response and immune-related side effects.
CONDITIONS
Brief Title
NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
Research Team
R
Robin Parihar, MD, PhD
M
Martha Arredondo
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here